



Sosei and Vectura Announce Start of Phase II Efficacy Study of QVA149

Tokyo, Japan and Chippenham, UK - 13 December 2007: Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the start, by Novartis, of a Phase II efficacy study of QVA149 for the treatment of chronic obstructive pulmonary disease (COPD)

QVA149 is a combination of NVA237, a once-daily long-acting muscarinic antagonist (LAMA) and indacaterol, a once-daily long-acting beta-2 agonist (LABA).

This second Phase II study is a randomised, double-blind, placebo-controlled, multi-centre trial to determine the effect of QVA149 on lung function in patients with moderate to severe COPD.

- Ends -

Enquiries:

Sosei Group Corporation

Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan

Hiroki MAEKAWA, Representative Executive Officer,

E-mail: hmaekawa@sosei.com

Tel: +81 3 5210 3399 Fax: +81 3 5210 3291

Sosei R&D Ltd.

Chesterford Research Park, Saffron Walden, CB10 1XL England

John DAFFURN, EVP Corporate Development,

E-mail: daffurnj@sosei.com

Tel: +44 1799 532 350 Fax: +44 1799 532 351